Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (342)
  • Open Access

    ARTICLE

    Exploring the effects of taurolidine on tumor weight and microvessel density in a murine model of osteosarcoma

    LISANNE K.A. NEIJENHUIS1,2,3,#, LEUTA L. NAUMANN4,#, SONIA A.M. FERKEL1, SAMUEL J.S. RUBIN1, STEPHAN ROGALLA1,*

    Oncology Research, Vol.32, No.7, pp. 1163-1172, 2024, DOI:10.32604/or.2024.050907

    Abstract Background: Osteosarcoma is the most common malignant primary bone tumor. The prognosis for patients with disseminated disease remains very poor despite recent advancements in chemotherapy. Moreover, current treatment regimens bear a significant risk of serious side effects. Thus, there is an unmet clinical need for effective therapies with improved safety profiles. Taurolidine is an antibacterial agent that has been shown to induce cell death in different types of cancer cell lines. Methods: In this study, we examined both the antineoplastic and antiangiogenic effects of taurolidine in animal models of osteosarcoma. K7M2 murine osteosarcoma cells were… More >

  • Open Access

    REVIEW

    Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment

    PAULINA CHMIEL1,2, ALEKSANDRA SłOWIKOWSKA1,2, ŁUKASZ BANASZEK1,2, ANNA SZUMERA-CIEćKIEWICZ3, BARTłOMIEJ SZOSTAKOWSKI1, MATEUSZ J. SPAłEK1,4,*, TOMASZ ŚWITAJ1, PIOTR RUTKOWSKI1, ANNA M. CZARNECKA1

    Oncology Research, Vol.32, No.7, pp. 1141-1162, 2024, DOI:10.32604/or.2024.050350

    Abstract Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult… More >

  • Open Access

    REVIEW

    Application of Plant-Based Coagulants and Their Mechanisms in Water Treatment: A Review

    Abderrezzaq Benalia1,2,*, Kerroum Derbal2, Zahra Amrouci2,3, Ouiem Baatache2, Amel Khalfaoui4, Antonio Pizzi5,*

    Journal of Renewable Materials, Vol.12, No.4, pp. 667-698, 2024, DOI:10.32604/jrm.2024.048306

    Abstract This review describes the mechanisms of natural coagulants. It provides a good understanding of the two key processes of coagulation-flocculation: adsorption and charge neutralization, as well as adsorption and bridging. Various factors have influence the coagulation/flocculation process, including the effect of pH, coagulant dosage, coagulant type, temperature, initial turbidity, coagulation speed, flocculation speed, coagulation and flocculation time, settling time, colloidal particles, zeta potential, the effects of humic acids, and extraction density are explained. The bio-coagulants derived from plants are outlined. The impact of organic coagulants on water quality, focusing on their effects on the physicochemical… More > Graphic Abstract

    Application of Plant-Based Coagulants and Their Mechanisms in Water Treatment: A Review

  • Open Access

    ARTICLE

    OPA3 overexpression modulates lipid droplet production and sensitizes colorectal cancer cells to bevacizumab treatment

    HONGBIAO WU*, DONGFANG LIU

    BIOCELL, Vol.48, No.6, pp. 971-980, 2024, DOI:10.32604/biocell.2024.049466

    Abstract Background: Colorectal cancer (CRC) represents a substantial risk to public health. Bevacizumab, the first US FDA-approved antiangiogenic drug (AAD) for human CRC treatment, faces resistance in patients. The role of lipid metabolism, particularly through OPA3-regulated lipid droplet production, in overcoming this resistance is under investigation. Methods: The protein expression pattern of OPA3 in CRC primary/normal tissues was evaluated by bioinformatics analysis. OPA3-overexpressed SW-480 and HCT-116 cell lines were established, and bevacizumab resistance and OPA3 effects on cell malignancy were examined. OPA3 protein/mRNA expression and lipid droplet-related genes were measured with Western blot and qRT-PCR. OPA3… More > Graphic Abstract

    OPA3 overexpression modulates lipid droplet production and sensitizes colorectal cancer cells to bevacizumab treatment

  • Open Access

    REVIEW

    Non-coding RNA as future target for diagnose and treatment of perineural invasion in cancers

    BINGJIE LI1,#, WENBO CAO1,2,3,#, JINJING XIAO1, YIXIAO CHEN1, QIYING WEI1, MINGJIN YUE4, SAIJUN MO1,2,3,*

    BIOCELL, Vol.48, No.6, pp. 923-934, 2024, DOI:10.32604/biocell.2024.049160

    Abstract Perineural invasion (PNI), a particularly insidious form of tumor metastasis distinct from hematogenous or lymphatic spread, has the capacity to extend well beyond the primary tumor site, infiltrating distant regions devoid of lymphatic or vascular structures. PNI often heralds a decrease in patient survival rates and is recognized as an indicator of an unfavorable prognosis across a variety of cancers. Despite its clinical significance, the underlying molecular mechanisms of PNI remain elusive, complicating the development of specific and efficacious diagnostic and therapeutic strategies. In the realm of cancer research, non-coding RNAs (ncRNAs) have attracted considerable… More >

  • Open Access

    ARTICLE

    Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy

    Yue-shen Wang*1, Jing Tian†1, Yong Han, Shu-mei Han, Sheng-bin Shi

    Oncology Research, Vol.24, No.2, pp. 129-135, 2016, DOI:10.3727/096504016X14618564639213

    Abstract We evaluated the efficacy and feasibility of the combination of gemcitabine plus vinorelbine in patients with platinum-based chemotherapy-refractory esophageal cancer. We enrolled 35 patients who received gemcitabine plus vinorelbine as second-line treatment after platinum-based chemotherapy failure between May 2009 and April 2012. Dosage: gemcitabine 1,000 mg/m2 plus vinorelbine 25 mg/m2 ; all drugs were administered on days 1 and 8 of a 21-day cycle, and this was continued until failure or unacceptable toxicity. A total of 125 cycles of treatment were administered, and all patients received at least two cycles of treatment (two to five cycles;… More >

  • Open Access

    REVIEW

    Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review

    Jiahao Su*, Meiqin Cai*, Wensheng Li*, Bo Hou, Haiyong He, Cong Ling,Tengchao Huang, Huijiao Liu, Ying Guo*

    Oncology Research, Vol.24, No.2, pp. 117-128, 2016, DOI:10.3727/096504016X14612603423511

    Abstract Glioblastoma (GBM) is the most common primary malignant brain tumor that nearly always results in a bad prognosis. Temozolomide plus radiotherapy (TEM+RAD) is the most common treatment for newly diagnosed GBM. With the development of molecularly targeted drugs, several clinical trials were reported; however, the efficacy of the treatment remains controversial. So we attempted to measure the dose of the molecularly targeted drug that could improve the prognosis of those patients. The appropriate electronic databases (PubMed, MEDLINE, EMBASE, and the Cochrane Library) were searched for relevant studies. A meta-analysis was performed after determining which studies… More >

  • Open Access

    ARTICLE

    Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse

    Annie Im, Ali Amjad, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Seah Lim, Alison Sehgal, Kathleen A. Dorritie, Robert L. Redner, Brian McLaughlin, Yongli Shuai, Shrina Duggal, Michael Boyiadzis

    Oncology Research, Vol.24, No.2, pp. 73-80, 2016, DOI:10.3727/096504016X14586627440156

    Abstract Relapsed acute myeloid leukemia (AML) represents a major therapeutic challenge. Achieving complete remission (CR) with salvage chemotherapy is the first goal of therapy for relapsed AML. However, there is no standard salvage chemotherapy. The current study evaluated outcomes and prognostic factors for achievement of CR in 91 AML patients in first relapse who were treated with the mitoxantrone–etoposide combination regimen. The overall response rate (CR and CRi) was 25%. Factors that were associated with a lower rate of CR included older age, shorter duration of first CR, low hemoglobin, and low platelet count. The median… More >

  • Open Access

    ARTICLE

    Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer

    Kazuyoshi Kawakami*, Takashi Yokokawa*, Kazuo Kobayashi*, Takahito Sugisaki*, Kenichi Suzuki*, Mitsukuni Suenaga, Kensei Yamaguchi, Ayaka Inoue, Yoshiaki Machida, Toshiharu Yamaguchi, Toshihiro Hama*

    Oncology Research, Vol.25, No.9, pp. 1625-1631, 2017, DOI:10.3727/096504017X15012905098071

    Abstract Adherence has become an important issue in modern oncology treatment. Most studies have included heterogeneous target tumor types, regimens, and therapy settings. Our study focused on capecitabine during capecitabine plus oxaliplatin (XELOX) treatment as an adjuvant therapy for colorectal cancer. The main aims of this study were to evaluate real-life adherence to capecitabine and to investigate candidate factors that might decrease adherence. We studied 338 consecutive patients who received XELOX treatment between December 1, 2011, and April 30, 2015, at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Our study assessed adherence… More >

  • Open Access

    ARTICLE

    Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients

    Baohong Yang*1, Aiying Qin†1, Kongyuan Zhang, Haipeng Ren*, Shuzhen Liu*, Xiaolei Liu§, Xiangpo Pan, Guohua Yu*

    Oncology Research, Vol.25, No.9, pp. 1601-1606, 2017, DOI:10.3727/096504017X14928634401178

    Abstract Epithelial growth factor receptor (EGFR) mutations are present in 10%–26% of non-small cell lung cancer (NSCLC) tumors and are associated with the response to tyrosine kinase inhibitors (TKIs). This study aimed to detect and quantify the presence of circulating tumor cells (CTCs) in EGFR-mutant NSCLC patients and investigate their possible role in providing prognostic information. Enrolled patients received erlotinib (150 mg) or gefitinib (250 mg) orally once daily as the first-line treatment. Serial blood samples were taken at baseline (CTC-d0) and on day 28 (CTC-d28) following the initiation of erlotinib/gefitinib for detection of CTCs using… More >

Displaying 1-10 on page 1 of 342. Per Page